Rein Therapeutics Inc (RNTX) Stock Price, Quote & News

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 802 1989

Website: www.reintx.com

Address:

12407 N. Mopac Expy., Suite 250 #390, Austin, United States

Dlslfl Jan. 30 at 10:52 PM

$RNTX bullish? :) u guy's all stupid Me too

0 · Reply

Dlslfl Jan. 27 at 4:46 AM

$RNTX have news?

0 · Reply

peepthestamp Jan. 24 at 1:33 AM

$RNTX

1 · Reply

hitmongreen Jan. 23 at 8:51 PM

$RNTX 🤔

0 · Reply

MomentumWins Jan. 20 at 1:54 PM

$SPY $QQQ looks like this will be green $RNTX

0 · Reply

DARKP00L Jan. 20 at 1:13 PM

$RNTX 08:08 on Jan. 20 2026 Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03 #tradeideas

0 · Reply

jamal1749 Jan. 20 at 1:09 PM

$RNTX trash

0 · Reply

jamal1749 Jan. 20 at 1:03 PM

$RNTX how did it go down on this news.

0 · Reply

premarketmaker Jan. 20 at 1:03 PM

$RNTX first resistance on ask - $3.05

0 · Reply

premarketmaker Jan. 20 at 1:02 PM

$RNTX very low amount of shares on the ask

0 · Reply

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Oct 9, 2025, 7:30 AM EDT - 4 months ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Sep 17, 2025, 7:30 AM EDT - 4 months ago

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Aug 19, 2025, 8:00 AM EDT - 6 months ago

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Aug 14, 2025, 5:00 PM EDT - 6 months ago

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Jun 24, 2025, 10:11 AM EDT - 8 months ago

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:18 PM EDT - 8 months ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial

May 27, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

May 19, 2025, 4:51 PM EDT - 9 months ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 15, 2025, 4:09 PM EDT - 9 months ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 28, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 23, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 15, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 7, 2025, 4:17 PM EDT - 10 months ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dlslfl Jan. 30 at 10:52 PM

$RNTX bullish? :) u guy's all stupid Me too

0 · Reply

Dlslfl Jan. 27 at 4:46 AM

$RNTX have news?

0 · Reply

peepthestamp Jan. 24 at 1:33 AM

$RNTX

1 · Reply

hitmongreen Jan. 23 at 8:51 PM

$RNTX 🤔

0 · Reply

MomentumWins Jan. 20 at 1:54 PM

$SPY $QQQ looks like this will be green $RNTX

0 · Reply

DARKP00L Jan. 20 at 1:13 PM

$RNTX 08:08 on Jan. 20 2026 Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03 #tradeideas

0 · Reply

jamal1749 Jan. 20 at 1:09 PM

$RNTX trash

0 · Reply

jamal1749 Jan. 20 at 1:03 PM

$RNTX how did it go down on this news.

0 · Reply

premarketmaker Jan. 20 at 1:03 PM

$RNTX first resistance on ask - $3.05

0 · Reply

premarketmaker Jan. 20 at 1:02 PM

$RNTX very low amount of shares on the ask

0 · Reply

premarketmaker Jan. 20 at 1:01 PM

$RNTX orphan drug -pulmonary fibrosis lower float

0 · Reply

BillionerOfKing Jan. 19 at 10:14 AM

$RNTX Current Stock Price: $1.22

0 · Reply

MomentumWins Jan. 2 at 3:00 PM

$RNTX bull market is back. we should see 2’s again

0 · Reply

SuperGreenToday Dec. 30 at 2:46 PM

$RNTX

1 · Reply

KnowledgeKing Dec. 25 at 9:56 AM

$RNTX Upside depends on translating ambition into measurable cadence, while management calibrates resource allocation to real demand signals. The upside case requires evidence, not projection.

0 · Reply

Lockedin2024 Dec. 16 at 9:24 PM

$RNTX time for some volume.. tomorrow maybe :)

0 · Reply

BrianWindsor Nov. 24 at 2:12 PM

Trying to make the science behind IPF more accessible. Here’s a quick breakdown of pulmonary fibrosis and why it matters for patients and investors following this field. 🎥 https://youtu.be/n6J_Cacf25w $RNTX

0 · Reply

Jobsworth Nov. 23 at 5:05 PM

$RNTX

0 · Reply

MomentumWins Nov. 19 at 4:24 AM

$RNTX Healthcare sector rotation in full force. This should catch fire for sure here

0 · Reply

DARKP00L Nov. 19 at 12:03 AM

$RNTX this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

Market Cap	34.17M
Revenue (ttm)	0.00
Net Income (ttm)	-62.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	71,500
Avg Vol	195,178
Day's Range	N/A - N/A
Shares Out	26.29M
Stochastic %K	17%
Beta	1.31
Analysts	Sell
Price Target	$10.00